Nuvo, Horizon Pharma deal

Horizon purchased from Nuvo U.S. rights to Pennsaid 2% diclofenac for $45 million in cash. Pennsaid, a topical NSAID gel formulation of diclofenac, is approved to treat pain associated with osteoarth...